This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Korea Research Institute of Bioscience and Biotechnology, Snu Rdb Foundation. Active years: 2017.
Company Filing History:
1 out of 334 
1 out of 549 
Years Active: 2017
Title: Hye Jin Min: Innovator in Monoclonal Antibody Research
Introduction
Hye Jin Min is a prominent inventor based in Daejeon, South Korea. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. Her innovative work focuses on the TM4SF5 protein, which has implications for cancer treatment and liver fibrosis.
Latest Patents
Hye Jin Min holds a patent for a monoclonal antibody specifically bound to the TM4SF5 protein. This invention relates to a novel monoclonal antibody that targets the human TM4SF5 protein. The patent encompasses various aspects, including polynucleotides coding for the antibody, an expression vector, and methods for preparing the antibody. Additionally, it outlines applications for treating liver fibrosis, cancer, and inhibiting cancer metastasis, as well as a diagnostic kit for cancer.
Career Highlights
Throughout her career, Hye Jin Min has worked with esteemed organizations such as the Korea Research Institute of Bioscience and Biotechnology and the SNU RDB Foundation. Her research has contributed to advancements in medical science and therapeutic applications.
Collaborations
Hye Jin Min has collaborated with notable colleagues, including Se Mi Kim and Sang Jick Kim. These partnerships have fostered a collaborative environment that enhances research outcomes and innovation.
Conclusion
Hye Jin Min's work in monoclonal antibody research exemplifies the impact of innovative thinking in biotechnology. Her contributions are paving the way for new treatments and diagnostic methods in the medical field.